Choose the experimental features you want to try

This document is an excerpt from the EUR-Lex website

Document 32016R1179

    Commission Regulation (EU) 2016/1179 of 19 July 2016 amending, for the purposes of its adaptation to technical and scientific progress, Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures (Text with EEA relevance)

    C/2016/4484

    OJ L 195, 20.7.2016, p. 11–25 (BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)

    Legal status of the document In force

    ELI: http://data.europa.eu/eli/reg/2016/1179/oj

    20.7.2016   

    EN

    Official Journal of the European Union

    L 195/11


    COMMISSION REGULATION (EU) 2016/1179

    of 19 July 2016

    amending, for the purposes of its adaptation to technical and scientific progress, Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures

    (Text with EEA relevance)

    THE EUROPEAN COMMISSION,

    Having regard to the Treaty on the Functioning of the European Union,

    Having regard to Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on classification, labelling and packaging of substances and mixtures, amending and repealing Directives 67/548/EEC and 1999/45/EC, and amending Regulation (EC) No 1907/2006 (1), and in particular Article 37(5) thereof,

    Whereas:

    (1)

    Part 3 of Annex VI to Regulation (EC) No 1272/2008 contains two lists of harmonised classification and labelling of hazardous substances. Table 3.1 lists the harmonised classification and labelling of hazardous substances based on the criteria set out in Parts 2 to 5 of Annex I to Regulation (EC) No 1272/2008. Table 3.2 lists the harmonised classification and labelling of hazardous substances based on the criteria set out in Annex VI to Council Directive 67/548/EEC (2).

    (2)

    Since Directive 67/548/EEC has been repealed with effect from 1 June 2015, Table 3.2 in Part 3 of Annex VI should be deleted. However, in order to ease the transition to full applicability of Regulation (EC) No 1272/2008, that deletion should not take effect until 1 June 2017.

    (3)

    Proposals for new, updated or deleted harmonised classification and labelling of certain substances have been submitted to the European Chemicals Agency (ECHA) pursuant to Article 37 of Regulation (EC) No 1272/2008. Based on the opinions on those proposals issued by the Committee for Risk Assessment of ECHA (RAC), as well as on the comments received from the parties concerned, it is appropriate to introduce, update or delete harmonised classification and labelling of certain substances.

    (4)

    With regard to the substance lead, RAC proposes in its scientific opinion of 5 December 2013 to classify it as toxic for reproduction category 1A. However, in view of the lack of certainty regarding the bioavailability of lead in the massive form, a distinction needs to be made between the massive form (particle size more than or equal to 1 mm) and the powder form (particle size of less than 1 mm). It is therefore appropriate to introduce a specific concentration limit (SCL) of ≥ 0,03 % for the powder form and a generic concentration limit (GCL) of ≥ 0,3 % for the massive form.

    (5)

    With regard to the copper substances, the environmental classification recommended in the RAC opinions of 4 December 2014 should be included in Annex VI to Regulation (EC) No 1272/2008 since sufficient scientific evidence is available justifying this new classification. However, the proposed M-factors for long-term aquatic hazard should not be included since they require further assessment by RAC in view of scientific data on aquatic toxicity presented by industry after the RAC opinion was forwarded to the Commission.

    (6)

    Regulation (EC) No 1272/2008 should be amended accordingly.

    (7)

    Compliance with the new harmonised classifications should not be required immediately, as a certain period of time will be necessary to allow suppliers to adapt the labelling and packaging of substances and mixtures to the new classifications and to sell existing stocks. This period of time will also be necessary to allow suppliers to adapt to and to comply with other legislative obligations resulting from the new harmonised classifications for substances such as those provided for in Article 22(f) or Article 23 of Regulation (EC) No 1907/2006 of the European Parliament and of the Council (3), those provided for in Article 50 of Regulation (EU) No 528/2012 of the European Parliament and of the Council (4) or those in Article 44 of Regulation (EC) No 1107/2009 of the European Parliament and of the Council (5).

    (8)

    In line with the transitional provisions of Regulation (EC) No 1272/2008 which allow the application of the new provisions at an earlier stage on a voluntary basis, suppliers should have the possibility of applying the new harmonised classifications and of adapting the labelling and packaging accordingly on a voluntary basis before the deadline for compliance.

    (9)

    The measures provided for in this Regulation are in accordance with the opinion of the Committee established by Article 133 of Regulation (EC) No 1907/2006,

    HAS ADOPTED THIS REGULATION:

    Article 1

    Regulation (EC) No 1272/2008 is amended as follows:

    (1)

    Annex VI is amended in accordance with the Annex to this Regulation;

    (2)

    in Annex VI, Table 3.2 is deleted.

    Article 2

    1.   This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.

    2.   This Regulation shall apply from 1 March 2018.

    Article 1(2) shall apply from 1 June 2017.

    3.   By way of derogation from paragraph 2, substances and mixtures may, before 1 March 2018, be classified, labelled and packaged in accordance with Regulation (EC) No 1272/2008 as amended by this Regulation.

    This Regulation shall be binding in its entirety and directly applicable in all Member States.

    Done at Brussels, 19 July 2016.

    For the Commission

    The President

    Jean-Claude JUNCKER


    (1)   OJ L 353, 31.12.2008, p. 1.

    (2)  Council Directive 67/548/EEC of 27 June 1967 on the approximation of laws, regulations and administrative provisions relating to the classification, packaging and labelling of dangerous substances (OJ 196, 16.8.1967, p. 1).

    (3)  Regulation (EC) No 1907/2006 of the European Parliament and of the Council of 18 December 2006 concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH), establishing a European Chemicals Agency, amending Directive 1999/45/EC and repealing Council Regulation (EEC) No 793/93 and Commission Regulation (EC) No 1488/94 as well as Council Directive 76/769/EEC and Commission Directives 91/155/EEC, 93/67/EEC, 93/105/EC and 2000/21/EC (OJ L 396, 30.12.2006, p. 1).

    (4)  Regulation (EU) No 528/2012 of the European Parliament and of the Council of 22 May 2012 concerning the making available on the market and use of biocidal products (OJ L 167, 27.6.2012, p. 1).

    (5)  Regulation (EC) No 1107/2009 of the European Parliament and of the Council of 21 October 2009 concerning the placing of plant protection products on the market and repealing Council Directives 79/117/EEC and 91/414/EEC (OJ L 309, 24.11.2009, p. 1).


    ANNEX

    Table 3.1 of Part 3 of Annex VI to Regulation (EC) No 1272/2008 is amended as follows:

    (a)

    the entries corresponding to index numbers 607-331-00-5 and 609-066-00-0 are deleted;

    (b)

    the entries corresponding to index numbers, 006-035-00-8, 029-002-00-X, 602-020-00-0, 602-033-00-1, 603-055-00-4, 604-030-00-0, 604-092-00-9, 605-013-00-0, 605-022-00-X, 606-014-00-9, 606-021-00-7, 607-056-00-0, 607-059-00-7, 607-157-00-X, 607-172-00-1, 607-375-00-5, 607-623-00-2, 613-166-00-X, 613-121-00-4, 616-011-00-4, 616-037-00-6 and 616-207-00-X are replaced by the following entries respectively:

    Index No

    International Chemical Identification

    EC No

    CAS No

    Classification

    Labelling

    Specific Conc. Limits, M-factors

    Notes

    Hazard Class and Category Code(s)

    Hazard statement Code(s)

    Pictogram, Signal Word Code(s)

    Hazard statement Code(s)

    Suppl. Hazard statement Code(s)

    ‘006-035-00-8

    pirimicarb (ISO); 2-(dimethylamino)-5,6-dimethylpyrimidin-4-yl dimethylcarbamate

    245-430-1

    23103-98-2

    Carc. 2

    Acute Tox. 3

    Acute Tox. 3

    Skin Sens. 1

    Aquatic Acute 1 Aquatic Chronic 1

    H351

    H331

    H301

    H317

    H400

    H410

    GHS08

    GHS06

    GHS09

    Dgr

    H351

    H331

    H301

    H317

    H410

     

    M = 10

    M = 100’

     

    ‘029-002-00-X

    dicopper oxide;

    copper (I) oxide

    215-270-7

    1317-39-1

    Acute Tox. 4

    Acute Tox. 4

    Eye Dam. 1

    Aquatic Acute 1

    Aquatic Chronic 1

    H332

    H302

    H318

    H400

    H410

    GHS07

    GHS05

    GHS09

    Dgr

    H332

    H302

    H318

    H410

     

    M = 100’

     

    ‘602-020-00-0

    1,2-dichloropropane;

    propylene dichloride

    201-152-2

    78-87-5

    Flam. Liq. 2

    Carc. 1B

    Acute Tox. 4*

    Acute Tox. 4*

    H225

    H350

    H332

    H302

    GHS02

    GHS08

    GHS07

    Dgr

    H225

    H350

    H332

    H302’

     

     

     

    ‘602-033-00-1

    chlorobenzene

    203-628-5

    108-90-7

    Flam. Liq. 3

    Acute Tox. 4

    Skin Irrit. 2

    Aquatic Chronic 2

    H226

    H332

    H315

    H411

    GHS02

    GHS07

    GHS09

    Wng

    H226

    H332

    H315

    H411’

     

     

     

    ‘603-055-00-4

    propylene oxide;

    1,2-epoxypropane; methyloxirane

    200-879-2

    75-56-9

    Flam. Liq. 1

    Carc. 1B

    Muta. 1B

    Acute Tox. 3

    Acute Tox. 3

    Acute Tox. 4

    STOT SE 3

    Eye Irrit. 2

    H224

    H350

    H340

    H331

    H311

    H302

    H335

    H319

    GHS02

    GHS08

    GHS06

    Dgr

    H224

    H350

    H340

    H331

    H311

    H302

    H335

    H319’

     

     

     

    ‘604-030-00-0

    bisphenol A;

    4,4′-isopropylidenediphenol

    201-245-8

    80-05-7

    Repr. 1B

    STOT SE 3

    Eye Dam. 1

    Skin Sens. 1

    H360F

    H335

    H318

    H317

    GHS08

    GHS05 GHS07

    Dgr

    H360F

    H335

    H318

    H317’

     

     

     

    ‘604-092-00-9

    phenol, dodecyl-, branched; [1]

    phenol, 2-dodecyl-, branched; [2]

    phenol, 3-dodecyl-, branched; [3]

    phenol, 4-dodecyl-, branched; [4]

    phenol, (tetrapropenyl) derivatives [5]

    310-154-3 [1]

    [2]

    [3]

    [4]

    [5]

    121158-58-5 [1]

    [2]

    [3]

    210555-94-5 [4]

    74499-35-7 [5]

    Repr. 1B

    Skin Corr. 1C

    Eye Dam. 1

    Aquatic Acute 1 Aquatic Chronic 1

    H360F

    H314

    H318

    H400

    H410

    GHS08

    GHS05

    GHS09

    Dgr

    H360F

    H314

    H410

     

    M = 10

    M = 10’

     

    ‘605-013-00-0

    chloralose (INN);

    (R)-1,2-O-(2,2,2-trichloroethylidene)-α-D-glucofuranose; glucochloralose; anhydroglucochloral

    240-016-7

    15879-93-3

    Acute Tox. 4*

    Acute Tox. 3

    STOT SE 3

    Aquatic Acute 1

    Aquatic Chronic 1

    H332

    H301

    H336

    H400

    H410

    GHS06

    GHS09

    Dgr

    H332

    H301

    H336

    H410

     

    M = 10

    M = 10

    C’

    ‘605-022-00-X

    glutaral; glutaraldehyde;

    1,5-pentanedial

    203-856-5

    111-30-8

    Acute Tox. 2

    Acute Tox. 3

    STOT SE 3

    Skin Corr. 1B

    Resp. Sens. 1

    Skin Sens. 1A

    Aquatic Acute 1

    Aquatic Chronic 2

    H330

    H301

    H335

    H314

    H334

    H317

    H400

    H411

    GHS06

    GHS05

    GHS08

    GHS09

    Dgr

    H330

    H301

    H335

    H314

    H334

    H317

    H410

    EUH071

    STOT SE 3; H335: 0,5 % ≤ C < 5 %

    M = 1’

     

    ‘606-014-00-9

    chlorophacinone (ISO);

    2-[(4-chlorophenyl)(phenyl)acetyl]-1H-indene-1,3(2H)-dione

    223-003-0

    3691-35-8

    Repr. 1B

    Acute Tox. 1

    Acute Tox. 1

    Acute Tox. 1

    STOT RE 1

    Aquatic Acute 1

    Aquatic Chronic 1

    H360D

    H330

    H310

    H300

    H372 (blood)

    H400

    H410

    GHS08

    GHS06

    GHS09

    Dgr

    H360D

    H330

    H310

    H300

    H372 (blood)

    H410

     

    Repr. 1B; H360D:

    C ≥ 0,003 %

    STOT RE 1; H372 (blood): C ≥ 0,1 %

    STOT RE 2; H373 (blood):

    0,01 % ≤ C < 0,1 %

    M = 1

    M = 1’

     

    ‘606-021-00-7

    N-methyl-2-pyrrolidone; 1-methyl-2-pyrrolidone

    212-828-1

    872-50-4

    Repr. 1B

    STOT SE 3

    Skin Irrit. 2

    Eye Irrit. 2

    H360D***

    H335

    H315

    H319

    GHS08

    GHS07

    Dgr

    H360D***

    H335

    H315

    H319

     

    STOT SE 3; H335: C ≥ 10 %’

     

    ‘607-056-00-0

    warfarin (ISO);

    4-hydroxy-3-(3-oxo-1-phenylbutyl)-2H-chromen-2-one; [1]

    (S)-4-hydroxy-3-(3-oxo-1-phenylbutyl)-2-benzopyrone; [2]

    (R)-4-hydroxy-3-(3-oxo-1-phenylbutyl)-2-benzopyrone [3]

    201-377-6

    [1]

    226-907-3

    [2]

    226-908-9

    [3]

    81-81-2 [1]

    5543-57-7

    [2]

    5543-58-8

    [3]

    Repr. 1A

    Acute Tox. 1

    Acute Tox. 1

    Acute Tox. 2

    STOT RE 1

    Aquatic Chronic 2

    H360D

    H330

    H310

    H300

    H372 (blood)

    H411

    GHS08

    GHS06

    GHS09

    Dgr

    H360D

    H330

    H310

    H300

    H372 (blood)

    H411

     

    Repr. 1A; H360D:

    C ≥ 0,003 %

    STOT RE 1; H372 (blood): C ≥ 0,5 %

    STOT RE 2; H373 (blood): 0,05 % ≤ C < 0,5 %’

     

    ‘607-059-00-7

    coumatetralyl (ISO); 4-hydroxy-3-(1,2,3,4-tetrahydro-1-naphthyl)coumarin

    227-424-0

    5836-29-3

    Repr. 1B

    Acute Tox. 2

    Acute Tox. 3

    Acute Tox. 2

    STOT RE 1

    Aquatic Chronic 1

    H360D

    H330

    H311

    H300

    H372 (blood)

    H410

    GHS08

    GHS06

    GHS09

    Dgr

    H360D

    H330

    H311

    H300

    H372 (blood)

    H410

     

    Repr. 1B; H360D: C ≥ 0,003 %

    STOT RE 1; H372 (blood): C ≥ 1,0 %

    STOT RE 2; H373 (blood) 0,1 % ≤ C < 1,0 %

    M = 10’

     

    ‘607-157-00-X

    difenacoum (ISO); 3-(3-biphenyl-4-yl-1,2,3,4-tetrahydro-1-naphthyl)-4-hydroxycoumarin

    259-978-4

    56073-07-5

    Repr. 1B

    Acute Tox. 1

    Acute Tox. 1

    Acute Tox. 1

    STOT RE 1

    Aquatic Acute 1

    Aquatic Chronic 1

    H360D

    H330

    H310

    H300

    H372 (blood)

    H400

    H410

    GHS08

    GHS06

    GHS09

    Dgr

    H360D

    H330

    H310

    H300

    H372 (blood)

    H410

     

    Repr. 1B; H360D:

    C ≥ 0,003 %

    STOT RE 1; H372 (blood): C ≥ 0,02 % STOT RE 2; H373 (blood):

    0,002 % ≤ C < 0,02 %

    M = 10

    M = 10’

     

    ‘607-172-00-1

    brodifacoum (ISO);

    4-hydroxy-3-(3-(4′-bromo-4-biphenylyl)-1,2,3,4-tetrahydro-1-naphthyl)coumarin

    259-980-5

    56073-10-0

    Repr. 1A

    Acute Tox. 1

    Acute Tox. 1

    Acute Tox. 1

    STOT RE 1

    Aquatic Acute 1

    Aquatic Chronic 1

    H360D

    H330

    H310

    H300

    H372 (blood)

    H400

    H410

    GHS08

    GHS06

    GHS09

    Dgr

    H360D

    H330

    H310

    H300

    H372 (blood)

    H410

     

    Repr. 1A; H360D:

    C ≥ 0,003 %

    STOT RE 1; H372 (blood): C ≥ 0,02 % STOT RE 2; H373 (blood):

    0,002 % ≤ C < 0,02 %

    M = 10

    M = 10’

     

    ‘607-375-00-5

    flocoumafen (ISO); reaction mass of: cis-4-hydroxy-3-(1,2,3,4-tetrahydro-3-(4-(4-trifluoromethylbenzyloxy)phenyl)-1-naphthyl)coumarin and trans-4-hydroxy-3-(1,2,3,4-tetrahydro-3-(4-(4-trifluoromethylbenzyloxy)phenyl)-1-naphthyl)coumarin

    421-960-0

    90035-08-8

    Repr. 1B

    Acute Tox. 1

    Acute Tox. 1

    Acute Tox. 1

    STOT RE 1

    Aquatic Acute 1

    Aquatic Chronic 1

    H360D

    H330

    H310

    H300

    H372 (blood)

    H400

    H410

    GHS08

    GHS06

    GHS09

    Dgr

    H360D

    H330

    H310

    H300

    H372 (blood)

    H410

     

    Repr. 1B; H360D:

    C ≥ 0,003 %

    STOT RE 1; H372 (blood): C ≥ 0,05 %

    STOT RE 2; H373 (blood):

    0,005 % ≤ C < 0,05 %

    M = 10

    M = 10’

     

    ‘607-623-00-2

    diisobutyl phthalate

    201-553-2

    84-69-5

    Repr. 1B

    H360Df

    GHS08

    Dgr

    H360Df’

     

     

     

    ‘613-166-00-X

    flumioxazin (ISO);

    2-[7-fluoro-3-oxo-4-(prop-2-yn-1-yl)-3,4-dihydro-2H-1,4-benzoxazin-6-yl]-4,5,6,7-tetrahydro-1H-isoindole-1,3(2H)-dione

    103361-09-7

    Repr. 1B

    Aquatic Acute 1

    Aquatic Chronic 1

    H360D

    H400

    H410

    GHS08

    GHS09

    Dgr

    H360D

    H410

     

    M = 1 000

    M = 1 000 ’

     

    ‘613-121-00-4

    chlorsulfuron (ISO); 2-chloro-N-[[(4-methoxy-6-methyl-1,3,5-triazin-2- yl)amino]carbonyl]benzenesulphonamide

    265-268-5

    64902-72-3

    Aquatic Acute 1

    Aquatic Chronic 1

    H400

    H410

    GHS09

    Wng

    H410

     

    M = 1 000

    M = 100’

     

    ‘616-011-00-4

    N,N-dimethylacetamide

    204-826-4

    127-19-5

    Repr. 1B

    Acute Tox. 4*

    Acute Tox. 4*

    H360D***

    H332

    H312

    GHS08

    GHS07

    Dgr

    H360D***

    H332

    H312’

     

     

     

    ‘616-037-00-6

    acetochlor (ISO); 2-chloro-N-(ethoxymethyl)-N-(2-ethyl-6-methylphenyl)acetamide

    251-899-3

    34256-82-1

    Carc. 2

    Repr. 2

    Acute Tox. 4

    STOT SE 3

    STOT RE 2

    Skin Irrit. 2

    Skin Sens. 1

    Aquatic Acute 1

    Aquatic Chronic 1

    H351

    H361f

    H332

    H335

    H373 (kidney)

    H315

    H317

    H400

    H410

    GHS08

    GHS07

    GHS09

    Wng

    H351

    H361f

    H332

    H335

    H373 (kidney)

    H315

    H317

    H410

     

    M = 1 000

    M = 100’

     

    ‘616-207-00-X

    polyhexamethylene biguanide hydrochloride;

    PHMB

    32289-58-0

    27083-27-8

    Carc. 2

    Acute Tox. 2

    Acute Tox. 4

    STOT RE 1

    Eye Dam. 1

    Skin Sens. 1B

    Aquatic Acute 1

    Aquatic Chronic 1

    H351

    H330

    H302

    H372 (respiratory tract) (inhalation)

    H318

    H317

    H400

    H410

    GHS08

    GHS06

    GHS05

    GHS09

    Dgr

    H351

    H330

    H302

    H372 (respiratory tract) (inhalation)

    H318

    H317

    H410

     

    M = 10

    M = 10’

     

    (c)

    the following entries are inserted in accordance with the order of the index numbers:

    Index No

    International Chemical Identification

    EC No

    CAS No

    Classification

    Labelling

    Specific Conc. Limits, M-factors

    Notes

    Hazard Class and Category Code(s)

    Hazard statement Code(s)

    Pictogram, Signal Word Code(s)

    Hazard statement Code(s)

    Suppl. Hazard statement Code(s)

    ‘005-020-00-3

    disodium octaborate anhydrous; [1]

    disodium octaborate tetrahydrate [2]

    234-541-0 [1]

    234-541-0 [2]

    12008-41-2 [1]

    12280-03-4 [2]

    Repr. 1B

    H360FD

    GHS08

    Dgr

    H360FD’

     

     

     

    ‘014-046-00-4

    e-glass microfibres of representative composition; [Calcium-aluminium-silicate fibres with random orientation with the following representative composition (% given by weight): SiO2 50,0-56,0 %, Al2O3 13,0-16,0 %, B2O3 5,8-10,0 %, Na2O < 0,6 %, K2O < 0,4 %, CaO 15,0-24,0 %, MgO < 5,5 %, Fe2O3 < 0,5 %, F2 < 1,0 %. Process: typically produced by flame attenuation and rotary process. (Additional individual elements may be present at low levels; the process list does not preclude innovation).]

    Carc. 1B

    H350i

    GHS08

    Dgr

    H350i

     

     

    A’

    ‘014-047-00-X

    glass microfibres of representative composition; [Calcium-aluminium-silicate fibres with random orientation with the following composition (% given by weight): SiO2 55,0-60,0 %, Al2O3 4,0-7,0 %, B2O3 8,0-11,0 %, ZrO2 0,0-4,0 %, Na2O 9,5-13,5 %, K2O 0,0-4,0 %, CaO 1,0-5,0 %, MgO 0,0-2,0 %, Fe2O3 < 0,2 %, ZnO 2,0-5,0 %, BaO 3,0-6,0 %, F2 < 1,0 %. Process: typically produced by flame attenuation and rotary process. (Additional individual elements may be present at low levels; the process list does not preclude innovation).]

    Carc. 2

    H351 (inhalation)

    GHS08

    Wng

    H351 (inhalation)

     

     

    A’

    ‘029-015-00-0

    copper thiocyanate

    214-183-1

    1111-67-7

    Aquatic Acute 1 Aquatic Chronic 1

    H400

    H410

    GHS09

    Wng

    H410

    EUH032

    M = 10’

     

    ‘029-016-00-6

    copper(II) oxide

    215-269-1

    1317-38-0

    Aquatic Acute 1

    Aquatic Chronic 1

    H400

    H410

    GHS09

    Wng

    H410

     

    M = 100’

     

    ‘029-017-00-1

    dicopper chloride trihydroxide

    215-572-9

    1332-65-6

    Acute Tox. 4

    Acute Tox. 3

    Aquatic Acute 1

    Aquatic Chronic 1

    H332

    H301

    H400

    H410

    GHS06

    GHS09

    Dgr

    H332

    H301

    H410

     

    M = 10’

     

    ‘029-018-00-7

    tetracopper hexahydroxide sulphate; [1]

    tetracopper hexahydroxide sulphate hydrate [2]

    215-582-3 [1]

    215-582-3 [2]

    1333-22-8 [1]

    12527-76-3 [2]

    Acute Tox. 4

    Aquatic Acute 1 Aquatic Chronic 1

    H302

    H400

    H410

    GHS07

    GHS09

    Wng

    H302

    H410

     

    M = 10’

     

    ‘029-019-01-X

    copper flakes (coated with aliphatic acid)

    Acute Tox. 3

    Acute Tox. 4

    Eye Irrit. 2

    Aquatic Acute 1

    Aquatic Chronic 1

    H331

    H302

    H319

    H400

    H410

    GHS06

    GHS09

    Dgr

    H331

    H302

    H319

    H410

     

    M = 10’

     

    ‘029-020-00-8

    copper(II) carbonate--copper(II) hydroxide (1:1)

    235-113-6

    12069-69-1

    Acute Tox. 4

    Acute Tox. 4

    Eye Irrit. 2

    Aquatic Acute 1

    Aquatic Chronic 1

    H332

    H302

    H319

    H400

    H410

    GHS07

    GHS09

    Wng

    H332

    H302

    H319

    H410

     

    M = 10’

     

    ‘029-021-00-3

    copper dihydroxide;

    copper(II) hydroxide

    243-815-9

    20427-59-2

    Acute Tox. 2

    Acute Tox. 4

    Eye Dam. 1

    Aquatic Acute 1

    Aquatic Chronic 1

    H330

    H302

    H318

    H400

    H410

    GHS06

    GHS05

    GHS09

    Dgr

    H330

    H302

    H318

    H410

     

    M = 10’

     

    ‘029-022-00-9

    bordeaux mixture;

    reaction products of copper sulphate with calcium dihydroxide

    8011-63-0

    Acute Tox. 4

    Eye Dam. 1

    Aquatic Acute 1

    Aquatic Chronic 1

    H332

    H318

    H400

    H410

    GHS07

    GHS05

    GHS09

    Dgr

    H332

    H318

    H410

     

    M = 10’

     

    ‘029-023-00-4

    copper sulphate pentahydrate

    231-847-6

    7758-99-8

    Acute Tox. 4

    Eye Dam. 1

    Aquatic Acute 1

    Aquatic Chronic 1

    H302

    H318

    H400

    H410

    GHS07

    GHS05

    GHS09

    Dgr

    H302

    H318

    H410

     

    M = 10’

     

    ‘082-013-00-1

    lead powder;

    [particle diameter < 1 mm]

    231-100-4

    7439-92-1

    Repr. 1A

    Lact.

    H360FD

    H362

    GHS08

    Dgr

    H360FD

    H362

     

    Repr. 1A; H360D: C ≥ 0,03 %’

     

    ‘082-014-00-7

    lead massive:

    [particle diameter ≥ 1 mm]

    231-100-4

    7439-92-1

    Repr. 1A

    Lact.

    H360FD

    H362

    GHS08

    Dgr

    H360FD

    H362’

     

     

     

    ‘605-040-00-8

    hydroxyisohexyl 3-cyclohexene carboxaldehyde (INCI); reaction mass of 4-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde and 3-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde; [1]

    4-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde; [2]

    3-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde [3]

    - [1]

    250-863-4 [2]

    257-187-9 [3]

    130066-44-3 [1]

    31906-04-4 [2]

    51414-25-6 [3]

    Skin Sens. 1A

    H317

    GHS07

    Wng

    H317’

     

     

     

    ‘607-716-00-8

    bromadiolone (ISO); 3-[3-(4′-bromobiphenyl-4-yl)-3-hydroxy-1-phenylpropyl]-4-hydroxy-2H-chromen-2-one

    249-205-9

    28772-56-7

    Repr. 1B

    Acute Tox. 1

    Acute Tox. 1

    Acute Tox. 1

    STOT RE 1

    Aquatic Acute 1

    Aquatic Chronic 1

    H360D

    H330

    H310

    H300

    H372 (blood)

    H400

    H410

    GHS08

    GHS06

    GHS09

    Dgr

    H360D

    H330

    H310

    H300

    H372 (blood)

    H410

     

    Repr. 1B; H360D:

    C ≥ 0,003 %

    STOT RE 1; H372 (blood): C ≥ 0,005 % STOT RE 2; H373 (blood):

    0,0005 % ≤ C < 0,005 %

    M = 1

    M = 1’

     

    ‘607-717-00-3

    difethialone (ISO);

    3-[3-(4′-bromobiphenyl-4-yl)-1,2,3,4-tetrahydronaphthalen-1-yl]-4-hydroxy-2H-1-benzothiopyran-2-one

    104653-34-1

    Repr. 1B

    Acute Tox. 1

    Acute Tox. 1

    Acute Tox. 1

    STOT RE 1

    Aquatic Acute 1

    Aquatic Chronic 1

    H360D

    H330

    H310

    H300

    H372 (blood)

    H400

    H410

    GHS08

    GHS06

    GHS09

    Dgr

    H360D

    H330

    H310

    H300

    H372 (blood)

    H410

    EUH070

    Repr. 1B; H360D:

    C ≥ 0,003 %

    STOT RE 1; H372 (blood): C ≥ 0,02 % STOT RE 2; H373 (blood):

    0,002 % ≤ C < 0,02 %

    M = 100

    M = 100’

     

    ‘607-718-00-9

    perfluorononan-1-oic acid [1] and its sodium [2] and ammonium [3] salts

    206-801-3 [1]

    [2]

    [3]

    375-95-1 [1]

    21049-39-8 [2]

    4149-60-4 [3]

    Carc. 2

    Repr. 1B

    Lact.

    Acute Tox. 4

    Acute Tox. 4

    STOT RE 1

    Eye Dam. 1

    H351

    H360Df

    H362

    H332

    H302

    H372 (liver, thymus, spleen)

    H318

    GSH08

    GSH07

    GHS05

    Dgr

    H351

    H360Df

    H362

    H332

    H302

    H372 (liver, thymus, spleen)

    H318’

     

     

     

    ‘607-719-00-4

    dicyclohexyl phthalate

    201-545-9

    84-61-7

    Repr. 1B

    Skin Sens. 1

    H360D

    H317

    GHS08

    GHS07

    Dgr

    H360D

    H317’

     

     

     

    ‘608-067-00-3

    3,7-dimethylocta-2,6-dienenitrile

    225-918-0

    5146-66-7

    Muta. 1B

    H340

    GHS08

    Dgr

    H340’

     

     

     

    ‘612-288-00-0

    bupirimate (ISO);

    5-butyl-2-ethylamino-6-methylpyrimidin-4-yl dimethylsulphamate

    255-391-2

    41483-43-6

    Carc. 2

    Skin Sens. 1B

    Aquatic Chronic 1

    H351

    H317

    H410

    GHS08

    GHS07

    GHS09

    Wng

    H351

    H317

    H410

     

    M = 1’

     

    ‘612-289-00-6

    triflumizole (ISO);

    (1E)-N-[4-chloro-2-(trifluoromethyl)phenyl]-1-(1H-imidazol-1-yl)-2-propoxyethanimine

    68694-11-1

    Repr. 1B

    Acute Tox. 4

    STOT RE 2

    Skin Sens. 1

    Aquatic Acute 1

    Aquatic Chronic 1

    H360D

    H302

    H373 (liver)

    H317

    H400

    H410

    GHS08

    GHS07

    GHS09

    Dgr

    H360D

    H302

    H373 (liver)

    H317

    H410

     

    M = 1

    M = 1’

     

    ‘616-218-00-X

    benzovindiflupyr (ISO); N-[9-(dichloromethylene)-1,2,3,4-tetrahydro-1,4-methanonaphthalen-5-yl]-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide

    1072957-71-1

    Acute Tox. 3

    Acute Tox. 3

    Aquatic Acute 1

    Aquatic Chronic 1

    H331

    H301

    H400

    H410

    GHS06

    GHS09

    Dgr

    H331

    H301

    H410

     

    M = 100

    M = 100’

     

    ‘616-219-00-5

    fluopyram (ISO); N-{2-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]ethyl}-2-(trifluoromethyl)benzamide

    658066-35-4

    Aquatic Chronic 2

    H411

    GHS09

    H411’

     

     

     

    ‘616-220-00-0

    pencycuron (ISO); 1-[(4-chlorophenyl)methyl]-1-cyclopentyl-3-phenylurea

    266-096-3

    66063-05-6

    Aquatic Acute 1

    Aquatic Chronic 1

    H400

    H410

    GHS09

    Wng

    H410

     

    M = 1

    M = 1’

     

    ‘617-023-00-2

    tert-butyl hydroperoxide

    200-915-7

    75-91-2

    Muta. 2

    H341

    GHS08

    Wng

    H341’

     

     

     


    Top